Temporal trends in hospitalizations and 30-day mortality in older patients during the COVID pandemic from March 2020 to July 2021

Sara Garcia-Ptacek MD, PhD^{1,2*}, Hong Xu MD, PhD^{1*}, Martin Annetorp MD², Viktoria Bäck Jerlardtz MD³, Tommy Cederholm MD, PhD^{1,2}, Malin Engström MD⁴, Miia Kivipelto MD, PhD^{1,2}, Lars Göran Lundberg MD⁵, Carina Metzner MD², Maria Olsson MD^{6,7}, Josefina Skogö Nyvang MD, PhD⁸, Carina Söhl Öberg MD⁹, Elisabet Åkesson MD, PhD^{10,11}, Dorota Religa MD, PhD^{1,2}, Maria Eriksdotter MD, PhD^{1,2}

¹Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden

²Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden

³Department of Geriatric medicine, Jakobsbergsgeriatriken, Stockholm, Sweden

⁴Department of Geriatric medicine, Sabbatsbergsgeriatriken, Stockholm, Sweden

⁵Department of Geriatric medicine, Dalengeriatriken Aleris Närsjukvård AB, Stockholm, Sweden

⁶Department of Geriatric medicine, Capio geriatrik Löwet, Stockholm, Sweden

⁷Department of Geriatric medicine, Capio geriatrik Sollentuna, Stockholm, Sweden

⁸Department of Geriatric medicine, Capio Geriatrik Nacka AB, Nacka, Sweden

⁹Department of Geriatric medicine, Handengeriatriken, Aleris Närsjukvård AB, Stockholm, Sweden

¹⁰Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden

¹¹R&D unit, Stockholms Sjukhem, Stockholm, Sweden

*Contributed equally

Correspondence to:

Sara Garcia-Ptacek MD, PhD
Division of Clinical Geriatrics,
Department of Neurobiology, Care Sciences and Society,
Karolinska Institutet, NEO, Blickagången 16, 141 52, Huddinge, Stockholm
E-mail: sara.garcia-ptacek@ki.se

Hong Xu, MD PhD
Division of Clinical Geriatrics,
Department of Neurobiology, Care Sciences and Society,
Karolinska Institutet, NEO, Blickagången 16, 141 52, Huddinge, Stockholm
E-mail: hong.xu.2@ki.se

Running Title: Temporal trends, geriatric care, COVID-19 and non-COVID patients

Word counts:

Abstract: 337; Text: 2990; References:30; Tables:2; Figures:3

KEY POINTS

Question: Multiple previous reports in different countries and settings have shown higher case fatality ratio or hospitalized case fatality ratio for COVID-19 in the first wave compared to the second wave of the pandemic. However, less is known about how the COVID-19 waves specifically affected the care of geriatric patients, including those with conditions other than COVID. .

Findings: The total number of hospitalizations was 5,320 for COVID-19 and 32,243 for non-COVID-cases. In COVID-patients, the 30-day mortality rate was highest at the beginning of the first wave (29% in March-April 2020), reached 17% at the second wave peak (November-December) followed by 11-13% in the third wave (March-July 2021). The mortality in non-COVID geriatric patients showed a similar trend, but of lower magnitude (5-10%). During the incidence peaks, COVID-19 hospitalizations displaced non-COVID geriatric patients.

Meaning: Hospital admissions and 30-day mortality after hospitalizations for COVID-19 increased in periods of high community transmission, albeit with decreasing mortality rates from wave 1 to 3, with a possible vaccination effect in wave 3. Thus, the healthcare system could not compensate for the high community spread of COVID-19 during the pandemic peaks, which also led to displacing care for non-COVID geriatric patients. These results are important for planning healthcare resources in future health emergencies.

67 ABSTRACT

68 **Importance:** Previous reports have suggested reductions in mortality risk from COVID-19
69 throughout the first wave of the COVID-19 pandemic. Mortality changes later in the
70 pandemic and pandemic effects on other types of geriatric hospitalizations are less studied.

71 **Objectives:** To describe the changes in hospitalizations and 30-day mortality in Stockholm
72 for patients 70+ receiving inpatient geriatric care for COVID-19 and other causes.

73 **Design:** Observational study. For patients 70 or older, we present the incidence of 30-day
74 mortality from COVID-19 in the Stockholm region, in relationship to geriatric
75 hospitalizations and 30-day mortality after admission for COVID-19 and other causes.

76 **Setting:** Hospitalizations for patients 70+ from geriatric clinics in Stockholm, Sweden
77 hospitalized for COVID-19 or other causes between March 2020 and July 31, 2021, were
78 included.

79 **Participants:** The total number of geriatric hospitalizations for patients 70+ was 5,320 for
80 COVID-19 and 32,243 for non-COVID-19 causes, corresponding to 4,565 individual
81 COVID-19 patients and 19,308 non-COVID-19 patients.

82 **Exposure(s):** The date of hospital admission to a geriatric clinic.
83 **Main Outcome(s) and Measure(s):** 30-day mortality after admission.

84 **Results:** In patients with COVID-19, the 30-day mortality rate was highest at the beginning of
85 the first wave (29% in March-April 2020), decreased as the first wave subsided (7% July-
86 August), increased again in the second wave (17% November-December), but failed to
87 increase as much in the third wave (11-13% March-July 2021). In non-COVID-19 geriatric
88 patients during the same period, the 30-day mortality presented a similar trend, but with a
89 smaller magnitude of variation (5 to 10%). The number of persons 70 or older testing positive
90 for COVID-19 in Stockholm reached two peaks in 2020 (April and December), fell in January
91 2021 and then increased again in March-April 2021.

92 **Conclusions and Relevance:** During the first and second waves, hospital admissions and 30-
93 day mortality after geriatric hospitalization for COVID-19 increased in periods of high
94 community transmission, although the mortality peak was lower in wave 2 than in wave 1.
95 The mortality for non-COVID geriatric cases was lower and more stable but also showed an
96 increase with the pandemic peaks.

97

98 **Key words:** COVID-19, geriatric, hospitalizations, 30-day mortality, displacing care

99

100

101

INTRODUCTION

During the first wave of the COVID-19 pandemic in Stockholm from March to July 2020, mortality for COVID-19 patients hospitalized in geriatric clinics decreased over time.¹ It was unclear at the time whether this was due to improved care or to patient selection of more severe cases earlier in the pandemic due to higher community incidence and an overburdened healthcare system. Our results from that first wave included only in-hospital mortality and did not explore how care for conditions other than COVID-19 was impacted by the pandemic. Age is among the strongest risk factors for COVID-19 and the infection fatality ratio after age 70 is substantial.^{2,3} Here, we present data on geriatric hospitalizations for COVID-19 and other causes, including 30-day mortality from admission and compare these to the incidence of COVID-19 and 30-day mortality from COVID-19 in the Stockholm region for persons 70+. We aim to describe how COVID-19 peaks affected geriatric patients 70 and older hospitalized both for COVID-19 and for other causes in Stockholm.⁴⁻⁷

In previous reports, COVID-19 mortality in hospitalized patients in Sweden increased with each pandemic wave and decreased between pandemic peaks.^{8,9} According to the Swedish Board of Health and Welfare, 60-day mortality after admission with COVID-19 decreased from a first-wave peak in March 2020 (25%) to a first nadir in August-September 2020 (10%), then rose again but to lower levels as the second wave progressed to a peak in December 2020 (20%), decreasing steadily afterwards.¹⁰ Decreasing mortality during the first pandemic wave was also observed in studies from the US,¹¹ with subsequent increases in mortality during pandemic surges.¹² A Spanish study reported that COVID-19 patients in the first wave were older, with more comorbidities and higher mortality than in the second wave.¹³ However, information is missing on mortality trends later in the pandemic, trends in older population and in geriatric patients with diagnoses other than COVID-19.

The aim of this study is to describe the changes over time in 30 day-mortality after admission of patients 70 years and older, hospitalized in 9 geriatric clinics in the Stockholm region from March 2020 to July 2021. We describe 30-day mortality both for patients hospitalized for COVID-19 and other causes over the three waves of the pandemic. Weekly hospitalizations for COVID-19 and other causes are presented and compared to the average weekly hospitalizations in the same geriatric clinics in 2019. These results are presented in the context of COVID-19 incidence and 30-day mortality and weekly hospitalizations from any cause in population 70 and over in the Stockholm region.

METHODS

Study population

We identified all hospitalizations of patients 70 years and older who were admitted to nine geriatric hospitals in Stockholm, Sweden, from March 6th, 2020, to July 31st, 2021. We excluded hospitalizations with a duration less than 24 hours or with an admission date after August 1st, 2021, to allow one month follow-up for mortality. A total of 5,320 hospitalizations for COVID-19 were included, together with 32,243 hospitalizations with non-COVID-19 diagnoses during the same period (**Figure 1**). This corresponded to 4,565 individual COVID-19 patients and 19,308 non-COVID-19 patients.

Exposure and Outcome

The study exposure was the hospital admission date (March 1st, 2020, to July 31st, 2021). The study outcome was 30-day mortality from admission. Patients were censored at death, or the end of follow-up (September 10th, 2021) whichever came first.

COVID-19 diagnosis and covariates

The diagnosis of COVID-19 followed clinical practice and was based on a positive reverse transcriptase-polymerase chain reaction (RT-PCR) analysis from nasopharyngeal swabs or, in case of a negative RT-PCR, typical clinical picture (including a consultation with a specialist in infectious diseases) and a CT scan with typical COVID-19 findings. All hospitalizations were included, and patients could have multiple hospitalizations. Hospitalizations for diagnoses other than COVID-19 to the same nine geriatric hospitals in Stockholm during the same period comprised the non-COVID group. We collected information on patient demographics, initial vital signs, medications, diagnoses at discharge, and 30-day mortality through the hospital electronic health records. 30-day mortality was defined from the date of admission to geriatrics.

COVID-19 incidence and mortality in the population 70 years and older in Stockholm

Information on confirmed cases with COVID-19 and mortality data in the population 70 and over in Stockholm was provided by the Swedish Board of Health and Welfare for research purposes (www.socialstyrelsen.se). Incidence data represents detected COVID-19 infections. Thirty-day mortality corresponds to deaths where COVID-19 was the main cause of death within 30 days of a positive test for persons 70 and over in the Stockholm region. Weekly hospitalizations for any cause in this population were also included as reference.

Weekly hospitalizations in 2019

For comparison, the average weekly hospitalizations registered in 2019 in the 9 geriatric clinics was presented. This was calculated by adding the total number of hospitalizations from all clinics (30,969) and dividing by 52 calendar weeks resulting in an average of 596 new hospitalizations per week.

Analysis

Summary statistics are displayed as mean $\pm$ standard deviation (SD) or median (interquartile range, IQR) or proportions.

30-day mortality rate is graphically presented in relationship to number of new admissions per week and COVID-19 incidence and mortality in the Stockholm region. Via logistic regression models, we assessed the effect of admission date on 30-day mortality, adjusted by age, sex, and medical treatment. Results were reported as odds ratios (OR) and 95% confidence interval (CI). Mortality rates were also compared against non-COVID-19 patients admitted to the same geriatric clinics during the same period.

All analyses were performed using R (<https://www.r-project.org>) and Stata version 17.0 (StataCorp, College Station, TX).

Ethical statement

The Swedish Ethical Review Authority approved the study (Dnr 2020-02146, and 2020-03345).

RESULTS

Characteristics and treatments at admission

Among the hospitalizations due to COVID-19, 87 % (4645 hospitalizations) had positive COVID-19 RT-PCR while 675 (13%) had a negative RT-PCR but fulfilled the clinical and radiological criteria for COVID-19. Patients hospitalized for COVID-19 had a median age of 84 (IQR 78-89) years, 53% were women and 6% of the patients had low saturation (<90%) at admission. The median duration of hospitalization was 9 days (IQR 6-13) (**Table 1**). The median age of geriatric hospitalizations for other (non-COVID-19) diagnoses was higher (85 IQR 79-90), and their hospital stays were shorter (6 days: IQR 4-9).

The total number of hospitalizations in the geriatric hospitals fell sharply at the beginning of the pandemic from a pre-pandemic weekly average of 596 in 2019. After this initial drop in the first wave, geriatric hospitalizations rallied, averaging 507 hospitalizations per week but without a sustained return to pre-pandemic levels. When COVID-19 cases increased, non-COVID-19 cases decreased accordingly (**Figure 2A**; **Supplemental table 1**).

Thirty-day mortality

Thirty-day mortality was highest at the beginning of the first wave (29% in March-April 2020 for COVID-19; 10% for non-COVID-19), decreased as the first wave subsided (7% July-August for COVID-19; 6% for non-COVID-19), and increased again for COVID cases in the second wave (17% November-December for COVID; 7% for non-COVID). Thirty-day mortality remained more stable in the third wave (11 to 13% March-July 2021 for COVID-19; 6% non-COVID-19) (**Table 1**).

Figure 2B shows the relationship between weekly COVID-19 hospital admissions to the nine geriatric hospitals and 30-day mortality. Mortality is lowest when few COVID-19 patients are hospitalized. **Figure 2C** presents the same relationship but for other geriatric patients. The lowest mortality rates appear in the inter-pandemic peaks, when COVID hospitalizations were lowest and non-COVID hospitalizations were highest.

Figure 3 shows the relationship between total COVID-19 cases and deaths in the Stockholm region and COVID-19 hospitalizations and deaths in the geriatric hospitals. The number of hospitalizations and the 30-day mortality rates increased with each pandemic peak and decreased between the peaks. The 30-day mortality rate after a positive test in Stockholm and the 30-day mortality rate after admission in the geriatric hospitals followed the pandemic and hospitalization curves. The smaller increase in the third wave probably indicates a vaccination effect.

Table 2 shows 30-day mortality risk from logistic regression, adjusted by age, sex, Charlson Comorbidity Index (CCI) and treatment. Compared with patients admitted to geriatrics for COVID-19 in November-December 2020, the risk of 30-day mortality was higher (OR 1.92, 95% CI 1.55-2.37) in March-April 2020, and lower in July August 2020 (OR 0.31, 0.15-0.66). A downward tendency appeared again in January-February 2021 (OR 0.70, 0.54-0.91), March-April 2021 (OR 0.72, 0.55-0.94) and May-June-July (OR 0.75, 0.49-1.13) (**Table 2**).

Thirty-day mortality in non-COVID-19 hospitalizations

Compared with hospitalizations in November-December 2020, hospitalizations in March-April 2020 had the highest mortality risk (OR 1.33; 95 CI 1.10-1.61), while hospitalizations from September-October 2020 (OR 0.67; 95% CI 0.55-0.82), March-April 2021 (0.81; 95% CI 0.67-0.99) and May-July 2021 (OR 0.82; 95% CI 0.69-0.98) presented lower risk, after adjusting (Table 1, Figure 2).

DISCUSSION

Several important observations appear in this study of hospitalized geriatric patients in Stockholm, Sweden. First, hospital admissions fell sharply at the beginning of the pandemic and didn't reach pre-pandemic levels throughout the whole observation period. Longer hospital stays in COVID-19 patients could be one reason for this finding. The length of hospitalization for COVID-19 patients was in line with previous international reports.^{11, 14} A reduction in elective procedures probably also contributed to the fall in admissions. The higher care burden for COVID-19 patients, together with the time required to don and doff protective equipment may have led to greater care burden and lower capacity to accept new cases. Additionally, hip and other osteoporotic fractures might have decreased in the population 70 and older due to the recommendations for this age group to avoid social contact.¹⁵ Hospital admissions further decreased during the summer months: the receding COVID-19 waves probably contributed to this reduction as did the customary reductions in available beds due to staff vacation which occur every summer.

Care seeking behaviour and the capacity of the healthcare system to detect and manage other diseases was affected during the pandemic: for example, the Swedish Stroke Register reports a decrease in the number of detected strokes in 2020 and 2021 compared to 2019.¹⁶ The Swedish registry for cognitive/dementia disorders reported a 30% reduction in diagnostic work-up.¹⁷ One US study included over 23 million emergency department (ED) visits for elderly Medicare beneficiaries, and compared hospital admission rate and changes in 30-day mortality between identical periods in 2018-19 and 2019-20.¹⁸ The drop in ED visits and increase in admission rate didn't correlate with local COVID-19 incidence. Mortality risk after ED visits also increased. The drop in ED visits, together with increased admission rate and mortality suggest that patients were avoiding seeking care, selecting for a sicker patient population in the ED. Furthermore, the lack of correlation with COVID-19 incidence suggests that patient behaviours (rather than hospital capacity) were responsible.¹⁸ Another US study found a decrease in ED visits for serious cardiovascular conditions early in the pandemic with gradual recovery (until October 2020)¹⁹. The same drop in cardiovascular visits was seen in Europe.^{20, 21} In contrast to the US study we saw a drop in hospitalizations in our cohort but not a complete recovery afterwards. We do not have data on ED visits so we cannot distinguish between patient care-seeking behaviours and triage in the ED. As seen in figure 2A COVID-19 patients displaced other diagnoses from geriatric care. The supply of geriatric hospitalizations in our cohort was inelastic, remained relatively stable during the pandemic and was lower than in 2019.

Second, 30-day mortality rose and fell with the pandemic waves. However, the peak mortality in geriatric clinics was higher in the first than in the second wave. This effect was more evident for COVID-19 patients but appeared also in non-COVID geriatric patients. Several studies, including our previous study, have noted a decrease in mortality throughout the first

wave of the pandemic^{22, 1}. A subsequent increase was observed again during the second wave in Sweden^{9, 23}. One study included more than 30,000 COVID-19 patients (including those admitted to the ICU) hospitalized between March and December 2020 in Sweden and showed that the 60-day case fatality rate for hospitalized cases decreased in the first wave but increased again in the second wave⁹. This study noted that the average age and comorbidities for hospitalized patients increased in the second wave, although they adjusted for these and other factors.

COVID-19 incidence was more severely underreported in the first wave in Sweden than later in the pandemic.²³ Some patients were treated in their nursing homes and never transferred to hospital, and this could have the effect of lowering the average age and comorbidities in the first wave but, interestingly, this change in average age is not present in our cohort. This may be explained by the fact that most patients admitted to inpatient geriatric hospital care lived in their own homes prior to admission. In this geriatric cohort, the proportion of patients presenting with oxygen saturation under 90% at baseline decreased from 8.9% in March-April 2020 to 2% in June, increasing again to 7.7% in December 2020. In our previous article we showed that low oxygen saturation at baseline explained some, but not all, of the temporal trend in mortality observed during the first wave.¹ Triage was probably harsher in the first wave leading to a sicker patient population and higher mortality. The alpha variant arrived in Sweden in December 2020, too late to explain the increase in 30-day mortality. Improvements in treatment may also explain a part of the reduction in mortality.

In an international context, studies from Africa²⁴, Italy²⁵, and Germany²⁶ showed a significant difference in COVID-mortality between the first wave and the second wave. Our temporal trend closely follows the German report, with high initial case fatal ratio, nadir in summer 2020 and subsequent increase in the second wave. In Germany, the first wave was smaller and led to fewer hospitalizations than the second, while the peaks in hospitalizations between the waves were more similar in Sweden. Despite this, the highest mortality in both studies was seen in the initial peak of the first wave²⁶. Another study examined raw case fatality ratio (CFR) in 53 countries or regions and showed decreased mortality in the second wave in 43 of them, including in Sweden.²⁷

Third, vaccinations probably changed the association between incidence and mortality in the third wave and averted the increase in 30-day mortality that had been apparent with increasing hospitalizations in the previous waves. The COVID-19 vaccination campaign began at the end of December 2020 in nursing homes and its effects on mortality were felt already in March-April 2021, as also seen in our cohort.²⁸

We cannot completely explain the changes in mortality. First, it should be noted that the 30-day mortality rate for COVID-19 patients reported in our study is based on a large cohort of older people in geriatric clinics in Stockholm, excluding nursing home patients treated in place, mild cases treated at home or cases treated in ICU or infectious disease wards instead of the geriatric clinics. Second, during the first wave of pandemic, the treatment and care of COVID-19 patients underwent great changes (<https://www.internetmedicin.se/behandlingsoversikter/infektion/covid-19/>), and these improvements are likely to be part of the reason for the decline in mortality during the first wave. In the second wave, the national guidelines for COVID-19 patients hospitalized in

Sweden didn't undergo major changes. In a previous report, we have shown that the prognosis of COVID-19 for the most frail during the first wave was ominous²⁹. It is possible that the most vulnerable and frail died during the first wave and thus contributing to lower mortality during the second wave.

We believe that due to the inelasticity of hospitalizations, increasing COVID-19 admissions during pandemic waves led to corresponding decreases in non-COVID admissions. This may have led to more stringent selection of admissions, a sicker patient population and greater overall mortality. Changes in treatment guidelines, particularly use of anticoagulants and corticosteroids led to improvement in the outcome of patients with COVID-19³⁰. However, except for vaccines and the third wave, these changes were implemented relatively early in the pandemic (before or during the summer of 2020) and cannot explain all the later changes in mortality.³⁰

Strengths and limitations:

In Sweden, geriatric hospitalizations are indicated on criteria of biological (and not chronological aging). Non-frail and non-comorbid older patients may have been hospitalized in other clinics (eg. infectious diseases) and not included in our cohort. Nine out of eleven existing geriatric clinics in Stockholm participated in the study. Living situation, comorbidities and medications were obtained from electronic health records with imperfect ascertainment. Medications were considered present if they were present or prescribed within 24h of hospitalization and would have included both newly prescribed medications and those removed after admission. We did not have information on vaccination, which would have been useful for assessing the decline of mortality in the third wave of the pandemic. Strengths of this study are the large geriatric cohort including nine out of eleven geriatric clinics in Stockholm treating patients with COVID-19. Also novel is the analysis of geriatric hospitalizations for other causes and the long study period including three pandemic waves over a period of 17 months.

Conclusion:

Thirty-day mortality was highest at the peak of the first wave, decreased in the inter-wave period and then increased again but to a lower peak in the second wave. The mortality increase of the third wave was probably averted by the vaccination campaign. Non-COVID mortality showed a similar trend but with lower magnitude. During COVID-19 incidence peaks, COVID-19 hospitalizations displaced non-COVID geriatric patients. Despite a massive organizational effort and the individual effort and sacrifice of health care workers, the healthcare system could not compensate for high community spread of COVID-19 during the pandemic peaks. Hospital admissions fell at the beginning of the pandemic and never returned to pre-pandemic levels, probably reflecting the greater complexity of COVID-19 patients compared to ordinary geriatric patients. The sustained fall in hospital admissions is particularly worrisome considering the backlog of cancelled and deferred care caused by the pandemic. COVID-19 disproportionally affects geriatric patients, and the broader pandemic has disrupted geriatric care.

ACKNOWLEDGEMENTS

Sara Garcia-Ptacek has received funding from the Swedish Stroke Association, the regional agreement on medical training and clinical research between the Stockholm County council and the Karolinska Institutet (ALF) and FORTE (#2017-01646). Hong Xu by StratNeuro (the Strategic Research Area Neuroscience-Karolinska Institutet, Umeå University and KTH) and the Center for Innovative Medicine (CIMED). Maria Eriksdotter by the Swedish medical research council grant (#2016-02317 and #2020-02014) and the regional agreement on medical training and clinical research between the Stockholm County council and the Karolinska Institutet (ALF), Dorota Religa by the Swedish Research Council (#2012-2291 and 2020-06101). The authors are grateful to the Swedish Board of Health and Welfare (Frida Broström and Henrik Nordin) for providing epidemiological data on COVID-19 in the population 70 years and older in Stockholm. The authors appreciate covidxix.org for their clear presentation of Swedish Covid-19 statistics and their help in finding relevant data for this study.

DECLARATION OF INTERESTS

None of the authors declare any conflict of interest pertinent to the present work.

REFERENCES

1. Xu H, Garcia-Ptacek S, Annetorp M, et al. Decreased Mortality Over Time During the First Wave in Patients With COVID-19 in Geriatric Care: Data From the Stockholm GeroCovid Study. *J Am Med Dir Assoc*. Aug 2021;22(8):1565-1573 e4. doi:10.1016/j.jamda.2021.06.005
2. Seoane B. A scaling approach to estimate the age-dependent COVID-19 infection fatality ratio from incomplete data. *PLoS One*. 2021;16(2):e0246831. doi:10.1371/journal.pone.0246831
3. Russell TW, Hellewell J, Jarvis CI, et al. Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020. *Euro Surveill*. Mar 2020;25(12):doi:10.2807/1560-7917.ES.2020.25.12.2000256
4. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. *The New England journal of medicine*. Jul 17 2020;doi:10.1056/NEJMoa2021436
5. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. *The New England journal of medicine*. Oct 8 2020;doi:10.1056/NEJMoa2007764
6. Paolisso P, Bergamaschi L, D'Angelo EC, et al. Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients. *Frontiers in pharmacology*. 2020;11:1124. doi:10.3389/fphar.2020.01124
7. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet (London, England)*. May 16 2020;395(10236):1569-1578. doi:10.1016/s0140-6736(20)31022-9
8. Strålin K, Wahlström E, Walther S, et al. Mortality trends among hospitalised COVID-19 patients in Sweden: A nationwide observational cohort study. *Lancet Reg Health Eur*. May 2021;4:100054. doi:10.1016/j.lanepe.2021.100054
9. Strålin K, Wahlström E, Walther S, et al. Second wave mortality among patients hospitalised for COVID-19 in Sweden: a nationwide observational cohort study. *medRxiv*. 2021:2021.03.29.21254557. doi:10.1101/2021.03.29.21254557
10. Welfare SBoHa. *Healthcare and Covid*. 2021. Accessed 2021-09-29. <https://www.socialstyrelsen.se/statistik-och-data/statistik/statistik-om-covid-19/statistik-om-slutenvard-av-patienter-med-covid-19/>
11. Nguyen JL, Benigno M, Malhotra D, et al. Hospitalization and mortality trends among patients with confirmed COVID-19 in the United States, April through August 2020. *Journal of Public Health Research*. 10/28 2021;doi:10.4081/jphr.2021.2244
12. Moon RC, Mackey RH, Cao Z, et al. Is COVID-19 Less Deadly Now? -- Trends of In-Hospital Mortality Among Hospitalized COVID-19 Patients in the United States. *Clin Infect Dis*. Sep 17 2021;doi:10.1093/cid/ciab830
13. Aznar-Gimeno R, Pano-Pardo JR, Esteban LM, et al. Changes in severity, mortality, and virus genome among a Spanish cohort of patients hospitalized with SARS-CoV-2. *Sci Rep*. Sep 22 2021;11(1):18844. doi:10.1038/s41598-021-98308-x
14. Vekaria B, Overton C, Wisniowski A, et al. Hospital length of stay for COVID-19 patients: Data-driven methods for forward planning. *BMC Infect Dis*. Jul 22 2021;21(1):700. doi:10.1186/s12879-021-06371-6
15. Rydberg EM, Möller M, Ekelund J, Wolf O, Wennergren D. Does the Covid-19 pandemic affect ankle fracture incidence? Moderate decrease in Sweden. *Acta Orthop*. Aug 2021;92(4):381-384. doi:10.1080/17453674.2021.1907517
16. Register TSS. *Covid-19 report Stroke*. 2021:4-5. Accessed 2021-09-29. <https://www.riksstroke.org/sve/forskning-statistik-och-verksamhetsutveckling/rapporter/ovriga-rapporter-2/>
17. SveDem Annual report 2021. . <https://www.ucruuse/svedem/om-svedem/arsrapporter>. 2021.

18. Smulowitz PB, O'Malley AJ, Khidir H, Zaborski L, McWilliams JM, Landon BE. National Trends In ED Visits, Hospital Admissions, And Mortality For Medicare Patients During The COVID-19 Pandemic. *Health Affairs*. 2021/09/01 2021;40(9):1457-1464. doi:10.1377/hlthaff.2021.00561
19. Pines JM, Zocchi MS, Black BS, et al. The effect of the COVID-19 pandemic on emergency department visits for serious cardiovascular conditions. *Am J Emerg Med*. Sep 2021;47:42-51. doi:10.1016/j.ajem.2021.03.004
20. De Rosa S, Spaccarotella C, Basso C, et al. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. *Eur Heart J*. Jun 7 2020;41(22):2083-2088. doi:10.1093/eurheartj/ehaa409
21. Sokolski M, Gajewski P, Zymliński R, et al. Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on Acute Admissions at the Emergency and Cardiology Departments Across Europe. *Am J Med*. Apr 2021;134(4):482-489. doi:10.1016/j.amjmed.2020.08.043
22. Strålin K, Wahlström E, Walther S, et al. Mortality trends among hospitalised COVID-19 patients in Sweden: A nationwide observational cohort study. *The Lancet Regional Health – Europe*. 2021;4doi:10.1016/j.lanepe.2021.100054
23. Statistics on hospitalizations of patients with Covid-19 (2021).
24. Salyer SJ, Maeda J, Sembuche S, et al. The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study. *Lancet (London, England)*. Apr 3 2021;397(10281):1265-1275. doi:10.1016/s0140-6736(21)00632-2
25. Dorrucci M, Minelli G, Boros S, et al. Excess Mortality in Italy During the COVID-19 Pandemic: Assessing the Differences Between the First and the Second Wave, Year 2020. *Frontiers in public health*. 2021;9:669209. doi:10.3389/fpubh.2021.669209
26. Gessler N, Gunawardene MA, Wohlmuth P, et al. Clinical outcome, risk assessment, and seasonal variation in hospitalized COVID-19 patients-Results from the CORONA Germany study. *PloS one*. 2021;16(6):e0252867. doi:10.1371/journal.pone.0252867
27. Fan G, Yang Z, Lin Q, Zhao S, Yang L, He D. Decreased Case Fatality Rate of COVID-19 in the Second Wave: A study in 53 countries or regions. *Transboundary and emerging diseases*. Mar 2021;68(2):213-215. doi:10.1111/tbed.13819
28. Sweden PHAo. *Vaccination coverage and reported cases (Vaccinationstäckning och rapporterade sjukdomsfall)*. 2021. 2021-05-20. Accessed 2021-11-08. <https://www.folkhalsomyndigheten.se/folkhalsorapportering-statistik/statistikdatabaser-och-visualisering/vaccinationsstatistik/statistik-for-vaccination-mot-covid-19/uppfoljning-av-vaccination/vaccinationstackning-och-rapporterade-sjukdomsfall/>
29. Hägg S, Jylhävä J, Wang Y, et al. Age, Frailty, and Comorbidity as Prognostic Factors for Short-Term Outcomes in Patients With Coronavirus Disease 2019 in Geriatric Care. *J Am Med Dir Assoc*. Nov 2020;21(11):1555-1559.e2. doi:10.1016/j.jamda.2020.08.014
30. "Swedish Society of Infectious disease specialists SHsaSfCM. *National care program for suspected or confirmed COVID-19 (Nationellt vårdprogram för misstänkt och bekräftad covid-19)*. 2021:28. Accessed 2021-11-23. <https://infektion.net/nationellt-varldprogram-covid19/#>

483 **Table 1. Hospitalizations for COVID-19 and other causes in patients 70 and over in**
484 **geriatric clinics**

	2020-2021	2020	2020	2020	2020	2020	2021	2021	2021
	Overall	Mar-Apr	May-June	July-Aug	Sep-Oct	Nov-Dec	Jan-Feb	Mar-Apr	May-June-July
COVID-19									
N	5320	990	813	117	118	1329	838	870	245
Age, year	84.0 (78.0, 89.0)	84.5 (79.0, 90.0)	85.0 (79.0, 91.0)	86.0 (81.0, 90.0)	85.5 (81.0, 91.0)	84.0 (79.0, 89.0)	83.0 (78.0, 89.0)	81.0 (76.0, 86.0)	81.0 (75.0, 88.0)
Women	2822 (53.0%)	535 (54.0%)	442 (54.4%)	63 (53.8%)	70 (59.3%)	723 (54.4%)	429 (51.2%)	436 (50.1%)	124 (50.6%)
CCI	2.0 (0.0, 3.0)	2.0 (0.0, 3.0)	2.0 (0.0, 3.0)	1.0 (0.0, 3.0)	1.0 (0.0, 3.0)	2.0 (0.0, 3.0)	2.0 (0.0, 3.0)	2.0 (0.0, 3.0)	2.0 (0.0, 3.0)
Hypertension	1777 (33.4%)	380 (38.4%)	310 (38.1%)	25 (21.4%)	43 (36.4%)	383 (28.8%)	268 (32.0%)	306 (35.2%)	62 (25.3%)
Diabetes	2014 (37.9%)	344 (34.7%)	287 (35.3%)	33 (28.2%)	32 (27.1%)	510 (38.4%)	331 (39.5%)	367 (42.2%)	110 (44.9%)
Chronic heart failure	761 (14.3%)	179 (18.1%)	152 (18.7%)	11 (9.4%)	21 (17.8%)	176 (13.2%)	115 (13.7%)	85 (9.8%)	22 (9.0%)
Myocardial Infarction	233 (4.4%)	43 (4.3%)	31 (3.8%)	1 (0.9%)	4 (3.4%)	57 (4.3%)	39 (4.7%)	44 (5.1%)	14 (5.7%)
Chronical pulmonary disease	709 (13.3%)	148 (14.9%)	108 (13.3%)	9 (7.7%)	20 (16.9%)	185 (13.9%)	114 (13.6%)	106 (12.2%)	19 (7.8%)
Asthma	185 (3.5%)	36 (3.6%)	24 (3.0%)	3 (2.6%)	8 (6.8%)	41 (3.1%)	28 (3.3%)	39 (4.5%)	6 (2.4%)
Cancer	331 (6.2%)	74 (7.5%)	49 (6.0%)	16 (13.7%)	10 (8.5%)	84 (6.3%)	41 (4.9%)	42 (4.8%)	15 (6.1%)
Stroke	307 (5.8%)	66 (6.7%)	58 (7.1%)	4 (3.4%)	9 (7.6%)	79 (5.9%)	38 (4.5%)	39 (4.5%)	14 (5.7%)
Atrial fibrillation	1061 (19.9%)	217 (21.9%)	195 (24.0%)	25 (21.4%)	26 (22.0%)	273 (20.5%)	151 (18.0%)	139 (16.0%)	35 (14.3%)
Initial S02<90%	342 (6.4%)	89 (9.0%)	39 (4.8%)	3 (2.6%)	7 (5.9%)	99 (7.4%)	50 (6.0%)	42 (4.8%)	13 (5.3%)
ACEI	1229 (23.1%)	246 (24.8%)	198 (24.4%)	21 (17.9%)	24 (20.3%)	276 (20.8%)	204 (24.3%)	190 (21.8%)	70 (28.6%)
ARB	1462 (27.5%)	251 (25.4%)	209 (25.7%)	32 (27.4%)	40 (33.9%)	378 (28.4%)	243 (29.0%)	248 (28.5%)	61 (24.9%)
β-blocker	2745 (51.6%)	531 (53.6%)	419 (51.5%)	65 (55.6%)	54 (45.8%)	681 (51.2%)	436 (52.0%)	430 (49.4%)	129 (52.7%)
CCB	1621 (30.5%)	295 (29.8%)	237 (29.2%)	34 (29.1%)	24 (20.3%)	412 (31.0%)	255 (30.4%)	286 (32.9%)	78 (31.8%)
Diuretics	2819 (53.0%)	563 (56.9%)	449 (55.2%)	66 (56.4%)	74 (62.7%)	672 (50.6%)	453 (54.1%)	410 (47.1%)	132 (53.9%)
Statins	2148 (40.4%)	380 (38.4%)	309 (38.0%)	40 (34.2%)	48 (40.7%)	548 (41.2%)	354 (42.2%)	380 (43.7%)	89 (36.3%)
Warfarin	388 (7.3%)	85 (8.6%)	61 (7.5%)	15 (12.8%)	7 (5.9%)	93 (7.0%)	62 (7.4%)	48 (5.5%)	17 (6.9%)
LMWH	2732 (51.4%)	410 (41.4%)	427 (52.5%)	39 (33.3%)	59 (50.0%)	772 (58.1%)	417 (49.8%)	509 (58.5%)	99 (40.4%)

NOAC	1745 (32.8%)	262 (26.5%)	285 (35.1%)	41 (35.0%)	34 (28.8%)	429 (32.3%)	315 (37.6%)	287 (33.0%)	92 (37.6%)
Glucocorticoids	1492 (28.0%)	151 (15.3%)	148 (18.2%)	23 (19.7%)	31 (26.3%)	465 (35.0%)	250 (29.8%)	338 (38.9%)	86 (35.1%)
Antibiotics	1798 (33.8%)	369 (37.3%)	252 (31.0%)	41 (35.0%)	41 (34.7%)	426 (32.1%)	280 (33.4%)	288 (33.1%)	101 (41.2%)
Days of hospitalization	9.0 (6.0, 13.0)	9.0 (6.0, 14.0)	9.0 (6.0, 14.0)	9.0 (6.0, 13.0)	11.0 (8.0, 19.0)	9.0 (6.0, 14.0)	8.0 (6.0, 12.0)	7.0 (5.0, 11.0)	8.0 (5.0, 10.0)
30-day mortality	910 (17.1%)	282 (28.5%)	134 (16.5%)	8 (6.8%)	21 (17.8%)	228 (17.2%)	106 (12.6%)	99 (11.4%)	32 (13.1%)
Non-COVID									
N	32243	3177	3198	4191	4736	2770	3217	4028	6926
Age, year	85.0 (79.0, 90.0)	86.0 (80.0, 91.0)	86.0 (80.0, 91.0)	85.0 (79.0, 90.0)	85.0 (79.0, 90.0)	85.0 (80.0, 90.0)	85.0 (79.0, 90.0)	85.0 (79.0, 90.0)	85.0 (79.0, 90.0)
Women	19336 (60.0%)	1895 (59.6%)	1900 (59.4%)	2574 (61.4%)	2822 (59.6%)	1635 (59.0%)	1907 (59.3%)	2429 (60.3%)	4174 (60.3%)
CCI	1.0 (0.0, 3.0)	2.0 (0.0, 3.0)	1.0 (0.0, 3.0)	1.0 (0.0, 3.0)	1.0 (0.0, 3.0)	1.0 (0.0, 3.0)	1.0 (0.0, 3.0)	1.0 (0.0, 3.0)	1.0 (0.0, 3.0)
Hypertension	9804 (30.4%)	1150 (36.2%)	1050 (32.8%)	1305 (31.1%)	1388 (29.3%)	817 (29.5%)	930 (28.9%)	1138 (28.3%)	2026 (29.3%)
Diabetes	9080 (28.2%)	908 (28.6%)	844 (26.4%)	1174 (28.0%)	1360 (28.7%)	769 (27.8%)	887 (27.6%)	1147 (28.5%)	1991 (28.7%)
Chronic heart failure	5001 (15.5%)	668 (21.0%)	541 (16.9%)	627 (15.0%)	680 (14.4%)	430 (15.5%)	480 (14.9%)	622 (15.4%)	953 (13.8%)
Myocardial Infarction	1206 (3.7%)	160 (5.0%)	123 (3.8%)	163 (3.9%)	162 (3.4%)	102 (3.7%)	103 (3.2%)	140 (3.5%)	253 (3.7%)
Chronical pulmonary disease	3189 (9.9%)	447 (14.1%)	379 (11.9%)	417 (9.9%)	446 (9.4%)	225 (8.1%)	313 (9.7%)	345 (8.6%)	617 (8.9%)
Asthma	538 (1.7%)	76 (2.4%)	60 (1.9%)	56 (1.3%)	74 (1.6%)	46 (1.7%)	48 (1.5%)	70 (1.7%)	108 (1.6%)
Cancer	2173 (6.7%)	266 (8.4%)	246 (7.7%)	275 (6.6%)	289 (6.1%)	186 (6.7%)	219 (6.8%)	266 (6.6%)	426 (6.2%)
Stroke	2254 (7.0%)	257 (8.1%)	289 (9.0%)	316 (7.5%)	327 (6.9%)	188 (6.8%)	224 (7.0%)	282 (7.0%)	371 (5.4%)
Atrial fibrillation	6578 (20.4%)	896 (28.2%)	765 (23.9%)	851 (20.3%)	942 (19.9%)	557 (20.1%)	638 (19.8%)	714 (17.7%)	1215 (17.5%)
Initial S02<90%	991 (3.1%)	135 (4.2%)	100 (3.1%)	116 (2.8%)	153 (3.2%)	90 (3.2%)	87 (2.7%)	134 (3.3%)	176 (2.5%)
ACEI	7445 (23.1%)	745 (23.4%)	772 (24.1%)	924 (22.0%)	1049 (22.1%)	673 (24.3%)	768 (23.9%)	940 (23.3%)	1574 (22.7%)
ARB	8602 (26.7%)	803 (25.3%)	836 (26.1%)	1120 (26.7%)	1274 (26.9%)	737 (26.6%)	805 (25.0%)	1084 (26.9%)	1943 (28.1%)
β-blocker	17298 (53.6%)	1744 (54.9%)	1720 (53.8%)	2231 (53.2%)	2515 (53.1%)	1445 (52.2%)	1691 (52.6%)	2202 (54.7%)	3750 (54.1%)
CCB	9828 (30.5%)	947 (29.8%)	955 (29.9%)	1240 (29.6%)	1404 (29.6%)	847 (30.6%)	1018 (31.6%)	1245 (30.9%)	2172 (31.4%)
Diuretics	17667 (54.8%)	1740 (54.8%)	1746 (54.6%)	2229 (53.2%)	2562 (54.1%)	1475 (53.2%)	1745 (54.2%)	2275 (56.5%)	3895 (56.2%)
Statins	12580 (39.0%)	1181 (37.2%)	1272 (39.8%)	1541 (36.8%)	1810 (38.2%)	1077 (38.9%)	1328 (41.3%)	1569 (39.0%)	2802 (40.5%)

Warfarin	2440 (7.6%)	282 (8.9%)	252 (7.9%)	302 (7.2%)	361 (7.6%)	188 (6.8%)	283 (8.8%)	312 (7.7%)	460 (6.6%)
LMWH	5960 (18.5%)	622 (19.6%)	598 (18.7%)	786 (18.8%)	798 (16.8%)	584 (21.1%)	643 (20.0%)	783 (19.4%)	1146 (16.5%)
NOAC	9975 (30.9%)	942 (29.7%)	1012 (31.6%)	1245 (29.7%)	1463 (30.9%)	846 (30.5%)	959 (29.8%)	1245 (30.9%)	2263 (32.7%)
Glucocorticoids	5426 (16.8%)	585 (18.4%)	515 (16.1%)	675 (16.1%)	802 (16.9%)	439 (15.8%)	521 (16.2%)	669 (16.6%)	1220 (17.6%)
Antibiotics	11154 (34.6%)	1071 (33.7%)	1000 (31.3%)	1360 (32.5%)	1547 (32.7%)	986 (35.6%)	1111 (34.5%)	1469 (36.5%)	2610 (37.7%)
Days of hospitalization	6.0 (4.0, 9.0)	6.0 (4.0, 8.0)	7.0 (4.0, 9.0)	7.0 (4.0, 9.0)	6.0 (4.0, 9.0)	7.0 (5.0, 9.0)	7.0 (5.0, 9.0)	7.0 (4.0, 9.0)	6.0 (4.0, 8.0)
30-day mortality	2022 (6.3%)	309 (9.7%)	199 (6.2%)	263 (6.3%)	225 (4.8%)	193 (7.0%)	209 (6.5%)	231 (5.7%)	393 (5.7%)

Abbreviations: S02<90% peripheral oxygen saturation under 90%; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blockers; LMWH, low-molecular-weight heparin; NOAC, Non-vitamin-K antagonist oral anticoagulant. Days of hospitalization: median number of days hospitalized (interquartile range). 30-day mortality is calculated from the date of hospitalization.

Table 2 Odds ratios for 30-day mortality in geriatric patients with COVID-19 and other diagnoses throughout the pandemic.

	COVID-19		Non-COVID	
	OR	95%CI	OR	95%CI
Mar-Apr 2020	1.92***	1.55,2.37	1.33**	1.10,1.61
May-June 2020	0.91	0.72,1.17	0.85	0.69,1.05
July-Aug 2020	0.31**	0.15,0.66	0.90	0.74,1.09
Sep-Oct 2020	0.99	0.59,1.64	0.67***	0.55,0.82
Nov-Dec 2020	ref		ref	
Jan-Feb 2021	0.70**	0.54,0.91	0.93	0.76,1.14
Mar-Apr 2021	0.72*	0.55,0.94	0.81*	0.67,0.99
May-June-July 2021	0.75	0.49,1.13	0.82*	0.69,0.98
Age				
70-79	ref		ref	
80-89	2.05***	1.68,2.51	1.62***	1.42,1.85
90+	3.06***	2.45,3.82	2.42***	2.11,2.77
Women	0.63***	0.54,0.74	0.68***	0.62,0.75
CCI	1.16***	1.12,1.20	1.18***	1.16,1.21
ACEI	0.94	0.78,1.14	0.84**	0.75,0.94
ARB	0.84	0.70,1.01	0.72***	0.64,0.80
β -blocker	1.20*	1.02,1.41	1.25***	1.13,1.39
CCB	0.80*	0.68,0.95	0.72***	0.65,0.80
Diuretics	1.32***	1.12,1.55	1.49***	1.34,1.65
Statins	0.70***	0.59,0.82	0.74***	0.66,0.82
Warfarin	1.15	0.87,1.52	1.06	0.91,1.25
LMWH	1.06	0.88,1.26	1.23***	1.10,1.38
NOAC	0.93	0.77,1.13	0.98	0.88,1.08
Glucocorticoids	1.22*	1.03,1.45	1.18**	1.05,1.33
Antibiotic	1.51***	1.29,1.75	1.27***	1.16,1.40

Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blockers; LMWH, low-molecular-weight heparin; NOAC, Non-vitamin-K antagonist oral anticoagulant.

Figure 1 Case selection flow chart

Figure 2 Hospitalizations and mortality throughout the COVID-19 pandemic for persons aged 70 and above

A) Number of weekly hospitalizations of patients 70 and above in nine geriatric clinics in Stockholm from March 2020 to July 2021.

B) 30-day COVID-19 mortality in relationship to weekly hospitalizations in geriatric clinics in patients 70 and above

C) 30-day mortality and hospitalizations for non-COVID causes in geriatric clinics for patients 70 and over

Figure 3. Relationship between confirmed cases of COVID-19, hospitalizations, and deaths in Stockholm

559 eTable 1 COVID-19 cases, mortality and hospitalizations in Stockholm and in geriatric clinics for population 70 and above.

560

Week	COVID-19 positive cases in Stockholm	30-day COVID-19 mortality Stockholm	COVID-19 hospitalizations in Stockholm	Total hospitalizations in Stockholm	COVID-19 geriatric hospitalizations	30-day mortality after geriatric hospitalization for COVID-19	Other diagnoses, geriatric hospitalizations	30-day mortality after geriatric hospitalization, non-COVID-19	Total geriatric hospitalizations
March 1, 2020							28	3	28
March 2, 2020			11	2 718	6	0	642	53	648
March 9, 2020	40	X	67	2 515	15	4	529	51	544
March 16, 2020	231	22	268	2 364	38	17	417	49	455
March 23, 2020	557	102	550	2 237	111	39	307	40	418
March 30, 2020	675	213	724	2 130	178	67	264	18	442
April 6, 2020	763	345	735	2 120	175	46	256	33	431
April 13, 2020	709	305	643	2 116	172	47	246	28	418
April 20, 2020	598	233	620	2 260	187	41	280	17	467
April 27, 2020	420	207	465	2 030	141	25	278	21	419
May 4, 2020	392	147	464	2 245	144	28	311	28	455
May 11, 2020	293	117	412	2 120	141	13	324	32	465
May 18, 2020	286	85	322	1 999	112	26	333	18	445
May 25, 2020	262	67	302	2 186	97	25	346	24	443
June 1, 2020	240	77	289	2 277	94	15	409	25	503
June 8, 2020	196	49	240	2 320	88	14	401	19	489
June 15, 2020	154	42	149	2 081	51	2	392	19	443
June 22, 2020	131	27	124	2 235	42	6	445	21	487
June 29, 2020	53	18	87	2 187	35	3	474	33	509
July 6, 2020	40	11	57	2 125	28	1	487	28	515

July 13, 2020	31	7	44	2 018	12	1	469	26	481
July 20, 2020	35	7	38	2 010	10	1	471	28	481
July 27, 2020	18	4	37	2 078	12	0	464	50	476
August 3, 2020	27	5	29	2 136	12	1	468	26	480
August 10, 2020	19	X	21	2 145	9	x	476	31	485
August 17, 2020	12	5	17	2 336	6	0	494	29	500
August 24, 2020	9	X	11	2 453	4	0	494	19	498
August 31, 2020	15	X	19	2 420	3	0	455	23	458
September 7, 2020	6	X	10	2 552	2	x	535	20	537
September 14, 2020	33	X	16	2 567	1	0	542	35	543
September 21, 2020	55	X	24	2 552	4	x	542	22	546
September 28, 2020	64	X	25	2 673	6	0	567	21	573
October 5, 2020	74	10	59	2 726	11	1	565	28	576
October 12, 2020	93	X	73	2 655	18	3	581	32	599
October 19, 2020	141	10	87	2 592	17	5	540	28	557
October 26, 2020	295	17	196	2 683	60	10	492	19	552
November 2, 2020	626	32	287	2 545	71	19	432	33	503
November 9, 2020	755	66	404	2 433	108	22	351	22	459
November 16, 2020	864	85	542	2 565	137	22	318	19	455

November 23, 2020	842	92	560	2 579	173	31	327	18	500
November 30, 2020	818	104	552	2 596	174	27	289	25	463
December 7, 2020	830	108	583	2 680	183	29	301	19	484
December 14, 2020	857	124	608	2 590	175	34	302	20	477
December 21, 2020	634	104	471	2 247	172	26	252	24	424
December 28, 2020	653	91	433	2 308	156	22	229	17	385
January 4, 2021	540	83	431	2 361	148	22	292	17	440
January 11, 2021	410	70	338	2 501	142	23	348	22	490
January 18, 2021	357	68	278	2 512	116	16	370	28	486
January 25, 2021	252	56	218	2 475	107	14	412	29	519
February 1, 2021	225	41	173	2 403	69	5	416	31	485
February 8, 2021	220	33	117	2 363	68	7	425	19	493
February 15, 2021	261	21	176	2 513	91	7	441	27	532
February 22, 2021	298	17	179	2 504	73	8	460	31	533
March 1, 2021	339	30	188	2 446	83	10	463	32	546
March 8, 2021	367	23	233	2 576	87	12	481	33	568
March 15, 2021	446	30	256	2 510	100	12	464	16	564

March 22, 2021	459	30	284	2 664	118	13	462	26	580
March 29, 2021	459	33	259	2 337	105	11	468	19	573
April 5, 2021	434	21	259	2 357	101	12	394	28	495
April 12, 2021	419	31	267	2 435	120	12	443	30	563
April 19, 2021	347	30	201	2 376	92	7	459	21	551
April 26, 2021	246	23	147	2 463	74	12	482	28	556
May 3, 2021	211	19	136	2 529	46	4	468	30	514
May 10, 2021	142	15	77	2 318	39	6	489	27	528
May 17, 2021	84	13	71	2 582	30	3	518	28	548
May 24, 2021	59	8	40	2 469	25	3	510	35	535
May 31, 2021	12	5	26	2 537	17	3	529	26	546
June 7, 2021	17	X	16	2 462	8	0	515	16	523
June 14, 2021	19	X	12	2 553	14	1	567	30	581
June 21, 2021	5	X	12	2 289	17	2	513	22	530
June 28, 2021	11	X	6	2 362	7	x	544	30	551
July 5, 2021	6	0	7	2 271	7	x	576	39	583
July 12, 2021	8	0	10	2 107	5	x	566	43	571
July 19, 2021	16	0	7	2 105	9	x	526	32	535
July 26, 2021	23	0	12	2 134	11	x	517	33	528

561
562
563
564
565
566